Global Food Allergy Market - 2024-2031

Overview

Global Food Allergy Market reached US$ 40.16 billion in 2023 and is expected to reach US$ 60.19 billion by 2031, growing with a CAGR of 5.19% during the forecast period 2024-2031.

The World Allergy Organization has documented a worldwide rise in the incidence of food allergies. Eggs, milk, wheat, fish and tree nuts are among the most prevalent allergies. Notably, seafood allergies are more prevalent in Asia than to Western nations. The market growth is linked to heightened awareness, unfulfilled medical demands and the launch of novel products.

Advanced diagnostic techniques, such as refined blood assays, skin prick tests and molecular diagnostics, promote allergy identification by augmenting precision and expediency. The global market for food allergy diagnostics and therapies exhibits favorable development potential. The prospects arise from the escalating demand for cost-effective treatment alternatives, developments in diagnostic technologies, the introduction of novel products such as epinephrine auto-injectors and the rising incidence of food allergies worldwide.

It is essential to tackle challenges, such as elevated medicine expenses, to guarantee ongoing market growth. The increase in financing for allergy treatments is driving progress in research and the availability of novel medications. In September 2022, COUR Pharmaceuticals successfully concluded a funding round of US$ 30 million, including Alpha Wave Ventures as a principal investor.

Dynamics

Rising Demand for Allergen-Free Products

The global rise in individuals circumventing allergens in food and beverages-approximately 500 million, with roughly 85 million in the US alone-indicates substantial growth potential in the food allergy market. In the last twenty years, the incidence of food allergies in American youths has escalated roughly fourfold compared to population growth. This phenomenon is not limited to US; evidence suggests a global rise in food allergies, especially in young children in both developed and developing countries.

Recent research by McKinsey & Company indicates that consumers, whether directly impacted by allergies or purchasing for someone who is, frequently encounter stress while navigating grocery aisles to evade allergens. Numerous individuals invest significant time analyzing product labels, with some even eschewing entire categories of products.

Moreover, these consumers often pay a premium for superior, allergen-free products, demonstrating a preference for smaller, allergy-aware firms over larger counterparts, while also seeking new product alternatives. In US, spending on allergen-free supermarket products above the average, with consumers allocating nearly US$ 19 billion yearly to alternatives or allergen-free items. This expenditure is expected to persist in its upward trajectory, highlighting the growth potential within the food allergy sector.

AI-Driven Innovations

The food allergy industry is expanding due to heightened awareness, mostly propelled by improvements in artificial intelligence (AI) technology. AI-driven solutions are improving awareness via accurate product labeling, ingredient assessment and tailored notifications for individuals with food allergies. The advancements enable individuals to promptly identify potential allergies in items, facilitating safe and informed decision-making.

AI-powered applications facilitate the scanning of labels and the analysis of substances, thereby enhancing allergen awareness and empowering individuals to effectively manage their dietary requirements-particularly those with severe, multiple or uncommon allergies who have difficulties in locating safe food alternatives. In addition to consumer items, AI-driven technologies including hyperspectral imaging, machine learning, computer vision and Fourier transform infrared spectroscopy are progressively employed in food service and production for allergen detection.

The non-invasive techniques facilitate the assessment of food quality and the identification of pollutants, thereby mitigating the risk of severe allergic reactions due to cross-contact in restaurants and processing facilities. As awareness of food allergens escalates, the food allergy market is poised for substantial expansion, with consumers and businesses alike emphasizing safety and transparency.

High Cost Of Diagnosis And Medication

The substantial expense associated with detecting and managing food allergies, especially peanut allergies, constitutes a considerable limitation on the food allergy industry. Research indicates that peanut allergies contribute an annual incremental healthcare cost of EUR 304-400 per individual, alongside supplementary expenses of EUR 794 for anaphylaxis treatment and EUR 470 for adrenaline auto-injector (AAI) prescriptions. For UK population, these expenses together total an estimated EUR 40-53 million annually. Such fees can restrict access to adequate diagnosis and continuous treatment, as individuals and healthcare institutions may contend with these additional financial pressures.

Rising prices can impede the implementation of preventative strategies, diagnostic procedures and innovative, possibly life-saving treatments. Individuals lacking adequate insurance or financial resources may neglect allergy testing and management, heightening their risk of severe reactions. This constraint affects both patients and hinders the growth of the food allergy market, as elevated costs diminish the accessibility and demand for sophisticated diagnostic equipment, treatments and allergen-free products, hence impeding market progress.

Segment Analysis

The global food allergy market is segmented based on food sources, diagnosis, treatment, distribution channel and region.

High Risk And Treatment Focus For Peanut Allergies

Peanut allergies dominate the food source segment due to the presence of potent allergenic proteins, including Ara h 1, Ara h 2 and Ara h 3, which are known for their ability to trigger severe allergic reactions. These proteins are particularly resilient, resisting both heat and digestion, which increases the likelihood of a reaction even in trace amounts. Peanut allergy is especially dangerous, as it can cause anaphylaxis-a severe, life-threatening allergic response-often with very small exposure to the allergen, making peanuts one of the most high-risk allergens globally.

This dominance is further underscored by the fact that peanut allergy is currently the only food allergy with an FDA-approved treatment, Palforzia, highlighting the seriousness and prevalence of peanut-related reactions. Other treatments, such as peanut oral immunotherapy, are in use to increase tolerance to peanut proteins but remain non-FDA-approved. This specialized treatment focus for peanut allergies, combined with the high-risk profile of peanut proteins, positions peanuts as a leading and particularly challenging subsegment in the food allergy market..

Geographical Penetration

Advancements in North America Diagnosis and Treatment

North America is a developed region characterized by substantial healthcare expenditure. It commands the global market owing to the increasing recognition of potential in allergy therapeutics. Consequently, American corporations are allocating resources to the research and development of anti-allergenic pharmaceuticals. Furthermore, emerging competitors are launching innovative items, resulting in heightened competition among manufacturers.

The significant prevalence of food allergies in US stimulates the need for better diagnosis and effective treatment solutions. US healthcare system is a market leader, recognized for its sophisticated infrastructure, extensive access to medical services and thorough allergy testing and treatments. Advancements in treatment have significantly contributed to market growth and development. Oral immunotherapy presents significant market potential.

Recently, US Food and Drug Administration (FDA) approved Palforzia for the treatment of peanut allergy in children. This oral immunotherapy seeks to mitigate allergic responses, including anaphylaxis, resulting from inadvertent peanut exposure. It is appropriate for children between the ages of four and seventeen who have a verified diagnosis of peanut allergy.

Competitive Landscape

The major global players in the market include Astellas Pharma, Inc., Aimmune Therapeutics, Meridian Medical Technologies, ALK-Abello Ltd, Medeca Pharma AB, bioMeriux SA, Omega Diagnostics Group PLC, HYCOR Biomedical, HOB Biotech Group Corp Ltd. and Cambridge Allergy Ltd.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict has intensified the worldwide food crisis, resulting in heightened awareness and demand for allergy testing as food insecurity amplifies worries regarding the safety of accessible food. Furthermore, logistical obstacles have postponed the distribution of allergy testing kits and associated diagnostic instruments, constraining market expansion in impacted areas.

Conversely, the persistent issue has prompted an escalation in governmental and humanitarian initiatives to bolster healthcare infrastructure in impacted regions, encompassing food allergy detection. Nonetheless, healthcare systems have been overwhelmed and resources are frequently redirected to urgent humanitarian requirements, so impeding the broad availability and accessibility of allergy diagnostic services. This has led to a heterogeneous effect on market expansion, presenting constraints in certain sectors while offering development prospects in others.

Food Source

• Dairy Products
• Poultry Products
• Peanuts
• Shellfish
• Wheat
• Others

Diagnosis

• Instruments
• Consumables
• Services
• Tests
  • In Vivo/Skin
  • In Vitro
• Others

Treatment

• Epinephrine
• Antihistamines
• Oral Immunotherapy
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In March 2024, Gold Standard Diagnostics introduced the inaugural product of the new allergy PowerLine tests: the SENSIStrip Gluten PowerLine Lateral Flow Device. The device features a sensitive detection technology utilizing a monoclonal antibody to identify gluten residues in food matrices, rinse water and swabs.
• In March 2024, ALS significantly enhanced and fortified its footprint in the Life Sciences sectors of Europe and US. ALS has acquired York Analytical Laboratories, located in Northeast US and Wessling Holding GmbH & Co., based in Western Europe.
• In February 2024, Merieux NutriSciences inaugurated a state-of-the-art laboratory for food analysis in Maringa, Brazil. The newly established facility possesses federal CGRE/IMMETRO accreditation in accordance with NBR ISO/IEC 17025 standards, aimed at assisting the food industry in achieving quality benchmarks.

Why Purchase the Report?

• To visualize the global food allergy market segmentation based on food source, diagnosis, treatment, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the food allergy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global food allergy market report would provide approximately 70 tables, 68 figures and 203 pages

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies